Vitamin D 3 upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) upregulated protein, and it is induced by various stresses. In human tumor tissues, VDUP1 expression was downregulated. Upon stimulation by growth-inhibitory signals such as TGF-b1 and 1,25(OH) 2 D 3 , its expression was rapidly upregulated as the cell growth was retarded. The transfection of VDUP1 in tumor cells reduced cell growth. The VDUP1 expression was also increased when the cell-cycle progression was arrested. Transfection of VDUP1 induced cellcycle arrest at the G0/G1 phase, indicating that VDUP1 possesses a tumor-suppressive activity. In addition, it was found that VDUP1 interacted with promyelocytic leukemia zinc-finger, Fanconi anemia zinc-finger, and histone deacetylase 1, which are known to be transcriptional corepressors. VDUP1 itself suppressed IL-3 receptor and cyclin A2 promoter activity. Taken together, these results suggest that VDUP1 is a novel antitumor gene which forms a transcriptional repressor complex.
Introduction
Tumor transformation involves the progressive accumulation of genetic and epigenetic alterations to tumor suppressor genes and oncogenes (Ross et al., 2000; Corn and El-Deiry, 2002) . The genes that are altered during tumorigenesis mainly affect cell growth, apoptosis, and the differentiation of tumor cells. Many of the genes involved in pathways that affect cell-cycle control and checkpoints are frequently inactivated in human cancer (Sherr, 2000) .
Promyelocytic leukemia zinc-finger (PLZF) is a sequence-specific transcriptional repressor differentially expressed during embryogenesis and myeloid differentiation (Li et al., 1997; Shaknovich et al., 1998; Costoya and Pandolfi, 2001 ). The amino terminus of PLZF contains a conserved motif known as the BTB (bric-abrac)/POZ (poxvirus and zinc-finger) domain, which may be involved in homodimerization and interaction with other corepressors (Melnick et al., 2002) . PLZFRARa is one of the translocation products in an alltrans-retinoic acid-resistant form of acute promyelocyte leukemia (APL) characterized with the t(11;17)(q23;q21) translocation. This aberrant retinoid receptor encoded from the t(11;17)(q23;q21) fusion gene is impaired in its ability to activate RARa target genes (Muller et al., 2000; Rego et al., 2000; Sainty et al., 2000) . Many of the BTB/POZ domain proteins, such as BCL-6 and HIC-1, also contain C-terminal zinc-fingers. This domain is involved in recruiting corepressor molecules, such as NCoR, SMRT, and Sin3A, which in turn, draw histone deacetylase (HDAC) to the promoter (David et al., 1998; Lin et al., 1998) .
Vitamin D 3 upregulated protein 1 (VDUP1) was differentially expressed in 1a, 25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 )-treated HL-60 leukemia cells (Chen and DeLuca, 1994) . According to the findings of recent works, VDUP1 expression decreased as rumors developed in the rat model (Yang et al., 1998) . In addition, VDUP1 expression was dramatically induced when cells were treated with some growth-inhibitory stimuli, including TGF-b1 and ROS stress (Junn et al., 2000) . Biochemical analysis showed that VDUP1 interacts with thioredoxin (Trx) to inhibit Trx functions and to prevent the interaction of Trx with other factors, such as PAG and ASK-1 (Junn et al., 2000; Nishiyama et al., 1999) . According to some researchers, these characteristics of VDUP1 render cells more vulnerable to various stresses.
In this paper, we have investigated the roles and expression pattern of VDUP1 in tumor cells. VDUP1 expression was reduced in various human tumor tissues, and VDUP1 inhibited tumor cell growth by arresting cells at the G0/G1 phase. This inhibitory effect on the cell cycle is due to the recruiting corepressor complex including PLZF.
Results

VDUP1 inhibited tumor cell growth
To identify the relation between VDUP1 expression and human cancers, we performed in situ hybridization with a digoxigenin-labeled VDUP1 antisense riboprobe in breast, lung, and stomach cancer tissues. There was strong expression of the VDUP1 gene in the bronchial submucosa (BS) of normal lung tissue and in the lymphatic nodule (LN) and lamina propria (LP) of normal stomach tissue. In all three representative cancers, VDUP1 gene expression either disappeared from the cancer region or was suppressed when it was compared with the normal regions ( Figure 1 ). Next, to investigate the roles of VDUP1 in tumor-cell growth, we examined the possible correlation between VDUP1 expression and the growth of several cancer cell lines.
We treated tumor cells with TGF-b1, which upregulated VDUP1 expression (Junn et al., 2000) . Among the tested, human stomach cancer cells, SNU-16 and SNU-620, responded well in terms of VDUP1 expression (data not shown). We treated cells with various concentrations of TGF-b1 for Northern blot analysis of hVDUP1 gene expression. In addition, the cell numbers were analysed at 24 h intervals after TGF-b1 treatment (Figure 2a) . Data from these experiments demonstrated that the TGF-b1 treatment inhibited the proliferation of the tumor cells concomitantly with a time-dependent expression of VDUP1 mRNA. However, the overexpression of VDUP1 alone did not induce cell apoptosis in SNU stomach rumor cells (data not shown). Previously, it was also observed that the overexpression of VDUP1 alone was not sufficient to induce the apoptosis of cells, but additional stimuli such as H 2 O 2 were required to induce cell apoptosis (Junn et al., 2000) . To verify that VDUP1 functions in the proliferation of the tumor cells, we infected the cells with retroviruses expressing Flag-tagged VDUP1. The expression of Flag-tagged VDUP1 was confirmed by
Figure 1 VDUP1 disappearance in tumor tissues. In situ hybridization of breast (a and b, cancer), lung (c, cancer; d, normal and cancer), and stomach (e, cancer; f, normal and cancer) tissues with VDUP1 probes. A strong expression of VDUP1 appeared in the normal regions (arrowhead), but not in cancer-bearing regions (arrow). BS, bronchial submucosa; CA, cancer region; IN, infiltrated inflammatory cells; GC, germinal center; H&E, hematoxylin-eosin; LN, lymphatic nodule; LP, lamina propria Western blot analysis (Figure 2b ). The experiments, using retroviral transduction to the stomach cancer cells, showed that VDUP1 overexpression made a direct inhibition of thymidine uptake and expansion of SNU-16 and SNU-620 cells (Figure 2b ). To confirm the observations that VDUP1 expression induced cellgrowth arrest, we further examined VDUP1 gene expression in 1,25(OH) 2 D 3 -treated human promyelocytic leukemia HL-60 cells. VDUP1 mRNA expression positively correlated with the 1,25(OH) 2 D 3 -or TGF-b1/ 1,25(OH) 2 D 3 -induced suppression of HL-60 cell proliferation (Figure 3a) . Again, retroviral transduction of VDUP1 to HL-60 cells also suppressed the HL-60 cell growth, as demonstrated by the thymidine incorporation assay (Figure 3b ). Taken together, these results indicate that VDUP1 itself has negative effects on tumor-cell growth, and that its expression is related to tumorigenesis.
VDUP1-induced cell-cycle arrest at G0/G1
To verify the effects of VDUP1 on cell-growth arrest further, we analysed the relation between VDUP1 expression and cell-cycle progression. First, we artificially induced cell-cycle arrest by serum withdrawal or by high-density cell culture. 293 and NIH3T3 cells expressed VDUP1 mRNA in a cell density-dependent fashion concomitantly with the G0/G1 arrest ( Figure 4a ). The serum-withdrawal experiment showed results similar to those of the high-density culture system. Serum starvation increased VDUP1 gene expression in a time-dependent manner and evoked G0/G1 arrest in the culture (Figure 4b ). We needed to determine whether or not the increase of VDUP1 mRNA expression was due to the activation of the VDUP1 transcription. Thus, we performed a CATreporter gene assay with a 1.8 kb (L) or 38 bp (S) upstream region of mouse VDUP1 promoter. A highdensity cell culture showed the induction of the VDUP1 promoter activity, but there was no induction of the Oct-1 promoter activity at the same conditions ( Figure 4c ). This finding suggests that VDUP1 gene expression is closely related to cell-cycle progression. To investigate the roles of VDUP1 in cell cycle further, we transfected VDUP1-GFP (green fluorescence protein) expression vector into 293 cells and checked cellcycle progression of GFP-expressing cells ( Figure 5 ). Transient transfection analysis with VDUP1-expression vectors in asynchronized 293 cells demonstrated that VDUP1 functioned as a direct inducer of cell-cycle arrest at G0/G1 ( Figure 5a ). Next, we expressed VDUP1 in synchronized 293 cells treated with deferoxamine, which is known to arrest cell cycle at G0/G1 (Figure 5b ). Then the cells were released from cell-cycle arrest by changing with fresh media. The cells expressing GFP were gated and analysed for cell-cycle progression. The cell-cycle progression of VDUP1-expressing cells was delayed at G0/G1 (51% at 5 h; 49% at 10 h) when compared with that of control cells (37% at 5 h; 35% at 10 h). This result confirmed the Roles of VDUP1 in inhibition of tumor cell growth SH Han et al previous observation that VDUP1 was an inducer of cell-cycle arrest at G0/G1. However, there was no apparent increase of sub-G1 portion in VDUP1-transfected cells, indicating that VDUP1 alone did not induce cell apoptosis in this condition. Cyclin A2 expression is required for S phase entrance and transition. Next, we performed a luciferase reporter assay with the plasmid bearing human cyclin A2 promoter in 293 cells. VDUP1 expression induced the downregulation of the cyclin A2 promoter (Figure 5c ). We normalized the luciferase activity with b-galactosidase activity. These data demonstrated that the inhibitory effects of VDUP1 on cell growth are due to a blocking cell-cycle progression.
Identification of VDUP1 interaction with transcriptional repressors, FAZF, PLZF, and HDAC1
For a more detailed analysis on the action mechanism of VDUP1 as a mediator of cell-growth arrest, we performed a yeast two-hybrid screen. We isolated Fanconi anemia zinc-finger (FAZF) clones from A20 B cell library (data not shown). To examine the intracellular interaction of VDUP1 with FAZF in the mammalian system, we performed a GST pull-down assay using GST-and FLAG-tagged expression vectors. VDUP1 specifically interacted with FAZF in 293 T cells (Figure 6a ). Based on the previous reports that FAZF has a transcriptional repressor complex in association with PLZF, histone deacetylase 1 (HDAC1), and other repressors (David et al., 1998; Hoatlin et al., 1999) , we set forth to examine whether or not VDUP1 interacts with the PLZF and HDAC1 corepressors. The GST pull-down assay and immunoprecipitation analysis demonstrated that VDUP1 interacted with PLZF ( Figure 6b ) and HDAC1 ( Figure 6c ) transcriptional repressors in transiently transfected 293 cells. These data imply that VDUP1 is a member of a transcriptional repressor complex. Next, we carried out the experiments for colocalization of VDUP1 and PLZF in HL-60 cells using confocal microscopy. The red image from PLZF expression due to Texas Red from anti-PLZF antibody complex superimposed the green image from the GFPtagged VDUP1 (Figure 6d ). The overlaid-speckled These results indicate that sVDUP1 is one part of a corepressor complex containing PLZF and FAZF.
VDUP1 functioned as a transcriptional repressor
To examine the functional interaction between the VDUP1 and PLZF corepressor complex in transcriptional activity, we performed a luciferase-reporter assay with pIL-3R-Luc containing four copies of PLZFbinding sites (Hoatlin et al., 1999) . We discovered that VDUP1 did the following: (1) VDUP1 expression inhibited the luciferase activity of pIL-3R-luciferase (Figure 7a ), (2) VDUP1 further inhibited the PLZFmediated reduction of pIL-3R-luciferase activity (Figure 7a ), and (3) VDUP1 further suppressed the activity of the human cyclin A2 promoter that contains PLZF-response elements (Yeyati et al., 1999) (Figure 7b ). These results demonstrated that VDUP1 functioned as a transcriptional repressor. In addition, when HL-60 cells were treated with TGF-b1/1,25(OH) 2 D 3 , the activity of cyclin A2 promoter was reduced, while the expression of VDUP1 and PLZF was increased (Figure 7c ), suggesting that TGF-b1/1,25 (OH) 2 D 3 increased the endogenous PLZF activity, presumably through upregulation of VDUP1. Furthermore, the PLZF binding activity to its binding site was increased by TGF-b1/1,25(OH) 2 D 3 treatment (Figure 7c ).
No effect of VDUP1 on the TGF-b1/VD3-induced differentiation
As described previously, VDUP1 is an upregulated gene by TGF-b1/(1,25(OH) 2 D 3 ), which induced HL-60 differentiation. PLZF is also known to regulate hematopoietic cell differentiation (Shaknovich et al., 1998; Melnick et al., 2000) . TGF-b1/(1,25(OH) 2 D 3 ) treatment increased the expression of CD14, a representative differentiation marker, of HL-60 cells concomitantly with a time-dependent expression of VDUP1 mRNA ( Figure 8a ). Next, we tested to determine whether or not VDUP1 expression affects the TGF-b1/(1,25(OH) 2 D 3 )-induced HL-60 differentiation. We cloned G418-resistant and PLZF-expressing clones by stable transfection and selection for 30 days (Figure 8b ). However, these clones did not show any change in CD14 expression when compared with the control cells (Figure 8b 
Discussion
When a class of genes loses its functions, the cells are more likely to and more susceptible to becoming malignant. Many genes, such as p53, Rb, p16
INK4a
, and ARF, have been identified as tumor-suppressor genes with frequent mutation in tumors (Banerjee et al., 1995; Bocchia et al., 1997) . For example, p53 controls the cellular responses to many stresses. Therefore, loss of the p53 function results in consequences for all of the pathways that normally control transcriptional targets in the cell cycle, DNA repair, and cell apoptosis (Kirshenbaum, 2001; Xu et al., 2001) . The regulation of cellular differentiation and cell-cycle progression is a key biological process for transformation. In normal physiology, differentiation entails a definitive withdrawal from the cell cycle. One of the common features of hematopoietic tumors is that they often display a block in differentiation. However, there is also growing evidence that differentiation and cell cycles are closely coupled. For example, pRB and P21, the proteins that critically regulate the cell cycle, also play important roles in cellular differentiation (Piek et al., 2001; Zheng and Lee, 2001 ).
In the present study, we observed that VDUP1 has an antitumor activity as a component of transcriptional corepressors. We have examined the expression pattern of VDUP1 in various conditions (Junn et al., 2000) . 1,25(OH) 2 D 3 , a hormonally active form of vitamin D 3 , induced VDUP1 expression in HL-60 cells (Chen and DeLuca, 1994) . VDUP1 was induced by various stresses, including H 2 O 2 , irradiation, and heat shock. It was also induced by serum starvation and in a confluent culture. 5-Fluoroucil and anisomycin, anticancer and antiproliferative agents, dramatically induced VDUP1 expression in cancer cells (Takahashi et al., 2002) . However, reportedly, its expression decreased in chemically induced rat mammary tumors (Yang et al., 1998) . VDUP1 locates on the mouse chromosome 3 band F2.2 that is syntenic with a region of human chromosome lq21, which is frequently mutated or lost in human cancers (Ludwig et al., 2001) . In situ hybridization analysis demonstrated that VDUP1 expression was reduced in various tumor tissues from stomach, breast, and lung cancer patients. Direct transfection to cancer cell lines induced the reduction of cell growth, confirming that VDUP1 itself had a tumor-suppressive effect. Previous biochemical analysis demonstrated that VDUP1 inhibited thioredoxin, which maintains cellular redox status (Nishiyama et al., 1999) and promotes the growth of tumor cells.
Another important function of VDUP1 is its role in cell-cycle progression. VDUP1 expression was increased in cell-cycle-arrested cells, and its overexpression induced cell-cycle arrest at G0/G1 and suppressed cyclin A promoter activity. This suppressive effect may be due to recruiting other corepressor complex including PLZF and FAZF. Cancer cells proliferate abnormally due to the derangement of cell-cycle control mechanisms. Cyclin A is one of the key components for the progression of a mitotic cell cycle. Its level begins to rise at the G1/S transition and continues to increase toward the G2/M phase. The expression of cyclin A is tightly regulated by corepressor activity and by unknown tissue-specific repressors of cyclin A promoter (Sherr, 2000) . VDUP1 seems to be a bridge molecule between transcription factors and corepressor complex including PLZF and HDAC that also interacts with PLZF (David et al., 1998; Lin et al., 1998 ; data not shown). Many transcriptional repressors reduce target genes by recruiting HDAC (Kramer et al., 2001; . They seem to be involved in targeting HDAC to their substrates or to transcriptional repressors. For example, RbAP46 and RbAP48 as integrals to the HDAC enzyme complex are responsible for the nucleosomal substrates (Taplick et al., 2001) . The role of VDUP1 in apoptosis is still controversial. Many apoptotic stimuli including anisomysin, oxidative stress, and suberoylanilide hydroxamic acid (Butler et al., 2002) induced the rapid upregulation of VDUP1. However, the effects of enforced VDUP1 overexpression on apoptosis were different depending on cell types. In NIH3T3 fibroblasts (Junn et al., 2000) , SNU stomach tumor cells, and 293 cells (Figure 5 ), VDUP1 overexpression was not sufficient to induce apoptosis. Meanwhile, apoptotic changes were observed after VDUP1 transfection into cardiomyocytes, in which VDUP1 expression was downregulated by oxidative stress (Wang et al., 2002) , suggesting that roles of VDUP1 and oxidative stress in cell apoptosis seem to be different depending on cell types.
VDUP1 is located in the multicompartments of cells-the cytosol and the nucleus-and its location seems to be changed depending on cellular conditions. For example, at low-density culture, it located in the cytosol and nucleus evenly, but at high-density culture, more VDUP1 was found in the nucleus (data not shown). These observations suggest that VDUP1 possesses various cellular functions, and that it is more than a physical linker. Interestingly, VDUP1 can induce PLZF gene expression in addition to interacting with each other. During hematopoietic development, PLZF expression is relatively high in CD34 þ bone marrow cells, immature lymphoid, and myeloid cells. However, in differentiated cells, its expression is downregulated, implying that it plays a role in the quiescent state of hematopoietic progenitors. The biological consequences of PLZF expression in hematopoietic cell lines include growth suppression, cell-cycle arrest in the G1/S phase, and differentiation blockade. It enhances cell apoptosis in IL-3-dependent 32DG/GM cells in the presence of IL-3. However, without IL-3, it increases cell survival by blocking cell apoptosis (Shaknovich et al., 1998) . This different action of PLZF may be due to an altered modification status, such as the protein phosphorylation of PLZF itself, or due to the other genes that interact with PLZF directly or indirectly. It implies that the regulation of PLZF expression or the functions by VDUP1 may differ depending on cellular conditions. More detailed analysis is required to elucidate the biological meaning of the physical interaction and expression modulation of PLZF by VDUP1.
APL is characterized by the blocking of myeloid differentiation (Olsson et al., 1996; Piazza et al., 2001) . PML-RAR-APL patients usually achieve complete remission upon retinoic acid treatment, but PLZF-RAR-APL patients respond very poorly. 1,25(OH) 2 D 3 can induce differentiation of myeloid cell lines, such as HL-60 and U937. A recent report (Ward et al., 2001) showed that PLZF inhibited 1,25(OH) 2 D 3 -induced U937 cell differentiation and VDRE-reporter activation by interacting with VDR. It inhibited 1,25(OH) 2 D 3 -induced CD14 expression in U937 cells, but it did not inhibit 1,25(OH) 2 D 3 -induced G1 arrest in U937 cells. Instead, the combined treatment of PLZF and 1,25(OH) 2 D 3 increased more G1 arrest than did 1,25(OH) 2 D 3 or PLZF alone. Our results showed that overexpression of PLZF also blocked the CD14 expression, but overexpression of VDUP1 did not affect the CD14 expression. According to Wang and Studzinski (2001) , the HL-60 differentiation induced by 1,25(OH) 2 D 3 is divided into at lease two stages. In the first stage, which lasts 24-48 h, the cells proliferate in the normal cell cycle, while the level of expression of monocytic markers, such as CD14, increases at this time. In the next stage, the onset of the G1 cell-cycle block and the CD11b expression become apparent, indicating that the cells are more differentiated. At the transient time between two stages, the erk1/2 activation is reduced and, consequently, some cell-cycle inhibitory proteins may be upregulated by 1,25(OH) 2 D 3 at the onset of the G1 block. VDUP1 expression was apparent at this time when cell-cycle arrest began (Junn et al., 2000) . Based on these observations, we can speculate that PLZF and VDUP1 are differently regulated and have different roles during hematopoietic cell differentiation and the tumorigenesis of APL.
In summary, our observations led to the following conclusions: (1) The data show that VDUP1 possesses antitumor effects by inducing cell-cycle arrest. This finding demonstrates that VDUP1 is a tumor-suppressive gene, which implies that it can be a novel therapeutical target for cancer therapy. (2) The fact that VDUP1 physically interacts with other corepressors suggests that it is another component of the corepressor complex. Thus, many potentials open up for its other functions in transcriptional regulation. Seoul, Korea) , HL-60, and Jurkat were maintained in RPMI supplemented with 10% FBS and the appropriate antibiotics. 293 and NIH3T3 cells were maintained in DMEM media in the presence of 10% FBS and antibiotics. All cells except SNU-16 and SNU-620 were obtained from American Type Culture Collection (Manassas, VA, USA).
Materials and methods
Cell culture
SNU
Preparation of retroviruses and infection to target cells
pMX-GFP was constructed by inserting PCR-amplified GFP cDNA from pEGFP to pMX in sites of BamHI and NotI. To construct a FLAG-tagged vector, pMX-VDUP1, human fulllength cDNA of VDUP1 was amplified by RT-PCR, inserted to EcoRI and XhoI sites of pCMV-Tag2b (Clonetech, Palo Alto, CA, USA), excised with NotI and XhoI, and then reinserted into the NotI and SalI sites of pMX. pLXSN-VDUP1 was previously described (Junn et al., 2000) . Retroviruses were produced using an amphotropic packaging cell line, Pheonix-Ampho (kindly provided by Dr GP Nolan, Stanford University) (Pear et al., 1993) . The cells were incubated in the retrovirus-containing media in the presence of 4 mg/ml polybrene for 8 h and fresh RPMI-1640 containing 10% FBS was added with an equal volume. We checked the infection efficiency with the parallel infection of the target cells by GFP-expressing retroviruses, and a retroviral titer used in all the experiments was more than 50% infectivity.
Northern blot and RT-PCR analysis
Northern blot analysis and RT-PCR were performed as previously described (Junn et al., 2000) . Briefly, 30 mg/lane of total RNA was fractionated by denaturing agarose gel electrophoresis and transferred to nylon membranes (Gene Screen Plus, NEN Life Science Products, Boston, MA, USA). The blots were hybridized with 32 P-labeled cDNA of fulllength VDUP1 overnight at 651C in the ExpressHyb solution (Clontech, Palo Alto, CA, USA), and properly washed. For RT-PCR, the amplifications were performed in a total volume of 30 ml containing 0.5 U of Tag DNA polymerase and 10 pmol of primers specific for human VDUP1 (5 0 -GGTGGATGT-CAATACCCCTG-3 0 and 5 0 -ATT GGC AAG GTA ACT GTG GC-3 0 ), TRX ( 
In situ hybridization
The fixed tissue sections were incubated with a hybridization solution containing 0.5 mg/ml tRNA, 20 mm Tris-HCl (pH 8.0), 2.5 mm EDTA, 1 Â Denhardt's solution, 0.3 m NaCl, 50% deionized formamide, 0.1% Tween 20, and 0.5 mg/ml digoxigenin-labeled VDUP1 antisense or sense riboprobes overnight at 551C. The tissue sections were further incubated with anti-digoxigenin alkaline phosphate-conjugated serum (diluted 1 : 500, Roche, Alameda, CA, USA) overnight at 41C. The final coloring reaction was done by adding a nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl-phosphate (BCIP) solution. Then, each sample section was mounted on the gelatin-coated slide and counterstained with 0.5% methyl green, dehydrated, and then coverslipped for viewing.
Synchronization and flow cytometric analysis
293 cells were transfected with pEGFP or pEGFP-VDUP1 by conventional calcium chloride method. Simultaneously, cells were treated with 30 mm deferoxamine to induce cell-cycle arrest at G0/G1. After 15 h, the cells were washed and supplemented with fresh medium. Then, the cells were harvested at various times for cell-cycle analysis. The cells were fixed with 70% ethanol for 1 h at À201C and washed once with PBS. The cells were resuspended in a 1 ml staining solution (0.1 mg/ml propidium iodide, 0.1 mg/ml RNase A in PBS) and stored in the dark for 30 min, followed by flow cytometric analysis. Only the GFP-positive cells were gated and subjected to cell-cycle analysis. To analyse the CD14 expression pattern, we cultured retrovirus-infected HL-60 cells in the presence of 100 nm 1,25(OH) 2 D 3 and 1 ng/ml TGF-b1 for 48 h. At the end of the culture period, we applied the cells to the standard FACS analysis with PE-labeled human anti-CD14 antibody (Becton Dickinson, Franklin Lakes, NJ, USA).
Promoter-reporter assay IL-3R-Luc containing four copies of PLZF binding site within the IL-3 receptor promoter was kindly provided by Dr JD Light (Mount Sinai School of Medicine, New York, USA). To construct pCyclinA2-Luc, a fragment of human cyclin A promoter (À516 to þ 245) was amplified by a pfu enzyme with the primers (forward primer: 5 0 -CACTTGAGTACTGTAT-TACTATGTGAGCTCCGTG-3 0 ; reverse primer: 5 0 -CCCAA-CATCACTGCTCCCGGGAG-3 0 ) and inserted to the pGL3-basic (Promega, Madison, WI, USA) with SacI and SmaI sites. Cells plated on 60 mm dishes were transiently transfected with indicated plasmids Lipofectamine Plus (GIBCO-BRL, Grand Island, NY, USA). A luciferase assay was carried out with Luciferase Assay Systems (Promega, Madison, WI, USA) 48 h later. For mouse VDUP1 promoter analysis, equal numbers of 293 cells were transfected with mouse VDUP1 promoter-CAT constructs (Ludwig et al., 2001) . After 12 h, the cell numbers were adjusted to the indicated concentrations with untransfected 293 cells. Then, the cells were incubated for another 48 h and harvested for CAT assay. To correct the transfection efficiency, a b-galactosidase assay and protein quantitation were also performed.
Electrophoretic mobility shift assay
Nuclear extracts were prepared from 1 Â 10 7 of HL-60 cells treated with TGF-b1 and 1,25(OH) 2 D 3 for 24 h. To prepare PLZF probes (5 0 -TCGAGGTATTCAGTACAGTACCAT-3 0 ) for the binding of PLZF, single-stranded oligonucleotides were annealed to form the oligomers. Radioactive double-stranded oligonucleotides labeled with T4 polynucleotide kinase and [g-32 P] ATP were incubated with nuclear extracts (7 mg) for 20 min in gel shift binding buffer (10 mm Tris-HCl, pH 7.5, 50 mm NaCl, 1 mm DTT, 1 mm EDTA, 5% glycerol, 2 mg of poly(dI-dC) poly(dI-dC), and 1 mg of BSA) in the presence or the absence of competitors for 20 min at room temperature. Then radiolabeled probe (X20 000 cpm) was added to the reaction mixture for an additional 10 min at room temperature. The binding products were electrophoresed at 4-5 V/cm on 6% polyacrylamide gel in 0.5 Â TBE buffer. The gel was dried and analysed by autoradiography.
Statistical analysis
The mean þ s.d. was determined for each treatment group more than three times for the individual experiments. Significant differences were tested with Dunnett's two-tailed t-test. *denotes Po0.05 and **means Po0.01.
